{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:00:28Z","timestamp":1789038028088,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>In psoriatic arthritis (PsA), the primary goal of treatment is clinical remission. This study aimed to characterize the molecular profile underlying the induced clinical remission in patients with PsA, comparing the remission state and the healthy condition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Whole blood transcriptomic analysis was performed on groups of 14 PsA patients in TNFi-induced clinical remission (DAPSA \u2264 4), 14 PsA patients with active disease (DAPSA &amp;gt; 14), and 14 healthy controls (HCs). Then, all differentially expressed genes (DEGs) derived from remission vs. HC comparison were analyzed for functional and biological characteristics by bioinformatics software. The gene expression of 12 genes was then validated by RT-qPCR in an extended cohort of 39 patients in clinical remission, 40 with active disease, and 40 HCs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The transcriptomic analysis of PsA remission vs. HCs highlighted the presence of 125 DEGs, and out of these genes, 24 were coding genes and showed a great involvement in immune system processes and a functional network with significant interactions. The RT-qPCR validation confirming the down- and upregulation of <jats:italic>FOS<\/jats:italic> (FC \u22122.0; <jats:italic>p<\/jats:italic> 0.005) and <jats:italic>CCDC50<\/jats:italic> (FC +1.5; <jats:italic>p<\/jats:italic> 0.005) genes, respectively, in line with their role in orchestrating inflammation and bone metabolism processes, may be related to PsA pathophysiology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The transcriptomic profile of clinical remission in PsA is similar to a healthy condition, but not identical, differing for the expression of <jats:italic>FOS<\/jats:italic> and <jats:italic>CCDC50<\/jats:italic> genes, which appears to play a key role in its achievement.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1274539","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T22:11:06Z","timestamp":1698444666000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Molecular profiling of clinical remission in psoriatic arthritis reveals dysregulation of FOS and CCDC50 genes: a gene expression study"],"prefix":"10.3389","volume":"14","author":[{"given":"Maria Maddalena","family":"Angioni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Floris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazio","family":"Cangemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Congia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Chessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela Rita","family":"Naitza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Piga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg217","article-title":"Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study","volume":"42","author":"McHugh","year":"2003","journal-title":"Rheumatology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.10.021","article-title":"Considerations for the definition of remission criteria in psoriatic arthritis","volume":"47","author":"Mease","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1096547","article-title":"Residual inflammation in psoriatic arthritis patients in stable minimal disease activity","volume":"9","author":"Macchioni","year":"2022","journal-title":"Front Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex344","article-title":"Remission in psoriatic arthritis-where are we now","volume":"57","author":"Coates","year":"2018","journal-title":"Rheumatol Oxf Engl"},{"key":"B8","doi-asserted-by":"publisher","first-page":"R119","DOI":"10.1186\/ar2327","article-title":"Ultrasonography, magnetic resonance imaging, radiography, and clinical assessment of inflammatory and destructive changes in fingers and toes of patients with psoriatic arthritis","volume":"9","author":"Wiell","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1054539","article-title":"Biomarkers in psoriatic arthritis: A meta-analysis and systematic review","volume":"13","author":"Wirth","year":"2022","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2019.108318","article-title":"Emerging molecular biomarkers for predicting therapy response in psoriatic arthritis: A review of literature","volume":"211","author":"Pouw","year":"2020","journal-title":"Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa405","article-title":"Broad proteomic screen reveals shared serum proteomic signature in patients with psoriatic arthritis and psoriasis without arthritis","volume":"60","author":"Leijten","year":"2021","journal-title":"Rheumatol (Oxford)."},{"key":"B12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13075-021-02545-4","article-title":"Clinical, laboratory, and genetic markers for the development or presence of psoriatic arthritis in psoriasis patients: a systematic review","volume":"23","author":"Mulder","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.723944","article-title":"Early origins of psoriatic arthritis: clinical, genetic and molecular biomarkers of progression from psoriasis to psoriatic arthritis","volume":"8","author":"Pennington","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X231192315","article-title":"Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis","volume":"15","author":"FitzGerald","year":"2023","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-00507-9","article-title":"Applying precision medicine to unmet clinical needs in psoriatic disease","volume":"16","author":"Jadon","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S291391","article-title":"Gene expression profiling of monozygotic twins affected by psoriatic arthritis","volume":"13","author":"Angioni","year":"2021","journal-title":"Open Access Rheumatol Res Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110845","article-title":"The classification for psoriatic arthritis (CASPAR) criteria \u2013 A retrospective feasibility, sensitivity, and specificity study","volume":"39","author":"Tillett","year":"2012","journal-title":"J Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20577","article-title":"Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI)","author":"Mease","year":"2011","journal-title":"Arthritis Care Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12940","article-title":"c-FOS expression analysis in pterygia cell spot arrays","volume":"36","author":"Mastronikolis","year":"2022","journal-title":"Vivo Athens Greece"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.14670\/HH-24.1451","article-title":"The transcription factor Fos: a Janus-type regulator in health and disease","volume":"24","author":"Durchdewald","year":"2009","journal-title":"Histol Histopathol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/ar2338","article-title":"Activator protein 1 (Fos\/Jun) functions in inflammatory bone and skin disease","volume":"10","author":"Zenz","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204386","article-title":"Partners in transcription: NFAT and AP-1","volume":"20","author":"Maci\u00e1n","year":"2001","journal-title":"Oncogene"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.159.3.1319","article-title":"Involvement of Rel, Fos, and Jun proteins in binding activity to the IL-2 promoter CD28 response element\/AP-1 sequence in human T cells","volume":"159","author":"McGuire","year":"1997","journal-title":"J Immunol Baltim Md 1950"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1067\/msy.2000.108063","article-title":"Interleukin-4 regulates macrophage interleukin-12 protein synthesis through a c-fos mediated mechanism","volume":"128","author":"Roy","year":"2000","journal-title":"Surgery"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.suppl_2.ii83","article-title":"Signalling in osteoclasts and the role of Fos\/AP1 proteins","volume":"62","author":"Wagner","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.2302\/kjm.53.78","article-title":"Osteoclasts, mononuclear phagocytes, and c-Fos: new insight into osteoimmunology","volume":"53","author":"Matsuo","year":"2004","journal-title":"Keio J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.031740","article-title":"Immunopathology of psoriasis and psoriatic arthritis","volume":"64","author":"Veale","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/416744a","article-title":"RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta","volume":"416","author":"Takayanagi","year":"2002","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/s1534-5807(02)00369-6","article-title":"Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts","volume":"3","author":"Takayanagi","year":"2002","journal-title":"Dev Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M010601200","article-title":"AP-1 and cbfa\/runt physically interact and regulate parathyroid hormone-dependent MMP13 expression in osteoblasts through a new osteoblast-specific element 2\/AP-1 composite element*","volume":"276","author":"Hess","year":"2001","journal-title":"J Biol Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1412","article-title":"Treatment of arthritis with a selective inhibitor of c-Fos\/activator protein-1","volume":"26","author":"Aikawa","year":"2008","journal-title":"Nat Biotechnol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M604184200","article-title":"Suppression of the ligand-mediated down-regulation of epidermal growth factor receptor by ymer, a novel tyrosine-phosphorylated and ubiquitinated protein*","volume":"281","author":"Tashiro","year":"2006","journal-title":"J Biol Chem"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2007.09.006","article-title":"Involvement of Ymer in suppression of NF-kappaB activation by regulated interaction with lysine-63-linked polyubiquitin chain","volume":"1783","author":"Bohgaki","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nature02794","article-title":"De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling","volume":"430","author":"Wertz","year":"2004","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/science.289.5488.2350","article-title":"Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice","volume":"289","author":"Lee","year":"2000","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.565163","article-title":"Myostatin promotes osteoclastogenesis by regulating ccdc50 gene expression and RANKL-induced NF-\u03baB and MAPK pathways","volume":"11","author":"Zhi","year":"2020","journal-title":"Front Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez427","article-title":"Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA","volume":"59","author":"Brahe","year":"2020","journal-title":"Rheumatol Oxf Engl"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41397-022-00290-8","article-title":"Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis","volume":"23","author":"Curry","year":"2023","journal-title":"Pharmacogenom J"},{"key":"B39","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/annrheumdis-2023-eular.2949","article-title":"POS0422 metabolomic fingerprint to discriminate remission from active disease and healthy controls in psoriatic arthritis","volume":"82","author":"Angioni","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00501-5","article-title":"Serum calprotectin as a promising inflammatory biomarker in psoriatic arthritis: a 1-year longitudinal study","volume":"10","author":"Li","year":"2023","journal-title":"Rheumatol Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2023-eular.5536","article-title":"AB1143 mir-10b expression in psoriatic arthritis patients with dapsa score remission or low disease activity","volume":"82","author":"K\u00f6ksal","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1274539\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T22:11:11Z","timestamp":1698444671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1274539\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2023.1274539"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1274539","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,27]]},"article-number":"1274539"}}